Marta Blázquez Estrada

List of Publications by Year
in descending order

37 papers	2,467 citations	361413 20 h-index	276875 41 g-index
44 all docs	44 docs citations	44 times ranked	3928 citing authors

#	Article	IF	Citations
1	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
2	LRRK2 R1441G in Spanish patients with Parkinson's disease. Neuroscience Letters, 2005, 382, 309-311.	2.1	97
3	Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. Journal of the Neurological Sciences, 2005, 236, 49-54.	0.6	97
4	Mutational screening of the mortalin gene (HSPA9) in Parkinson's disease. Journal of Neural Transmission, 2009, 116, 1289-1293.	2.8	74
5	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
6	Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neuroscience Letters, 2004, 370, 151-154.	2.1	65
7	Penetrance of Parkinson's Disease in <i>LRRK2</i> p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	3.9	57
8	Digenic parkinsonism: Investigation of the synergistic effects of PRKN and LRRK2. Neuroscience Letters, 2006, 410, 80-84.	2.1	52
9	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population‐Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
10	Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics, 2009, 10, 347-353.	1.4	41
11	Identification of sixteen novel candidate genes for late onset Parkinson's disease. Molecular Neurodegeneration, 2021, 16, 35.	10.8	41
12	Non‐motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease. European Journal of Neurology, 2020, 27, 1210-1223.	3.3	40
13	Therapeutic extradural cortical stimulation for Parkinson's Disease: Report of six cases and review of the literature. Clinical Neurology and Neurosurgery, 2009, 111, 703-707.	1.4	36
14	Directional Deep Brain Stimulation for Parkinson's Disease: Results of an International Crossover Study With Randomized, Double-Blind Primary Endpoint. Neuromodulation, 2022, 25, 817-828.	0.8	34
15	Analysis of the <i>Micro‐RNA‐133</i> and <i>PITX3</i> genes in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1234-1239.	1.7	33
16	Mitochondrial transcription factor A (TFAM) gene variation in Parkinson's disease. Neuroscience Letters, 2008, 432, 79-82.	2.1	30
17	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
18	No association between Parkinson's disease and three polymorphisms in the eNOS, nNOS, and iNOS genes. Neuroscience Letters, 2007, 413, 202-205.	2.1	25

#	Article	IF	Citations
19	5â€²-upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. Neurobiology of Disease, 2009, 33, 164-170.	4.4	24
20	Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease. Neuroscience Letters, 2002, 329, 149-152.	2.1	23
21	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Neurobiology of Aging, 2019, 76, 215.e9-215.e14.	3.1	21
22	Predictors of clinically significant quality of life impairment in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 118.	5.3	17
23	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	10.2	15
24	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinsonâ€™s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Personalized Medicine, 2021, 11, 626.	2.5	10
25	Constipation Predicts Cognitive Decline in Parkinsonâ€™s Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. Journal of Parkinson's Disease, 2022, 12, 315-331.	2.8	10
26	Predictors of Loss of Functional Independence in Parkinsonâ€™s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. Diagnostics, 2021, 11, 1801.	2.6	9
27	Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. Movement Disorders, 2007, 22, 389-392.	3.9	8
28	Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism. Neuroscience Letters, 2005, 380, 257-259.	2.1	7
29	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinsonâ€™s disease. BMC Neurology, 2021, 21, 477.	1.8	7
30	Present and Future of Parkinsonâ€™s Disease in Spain: PARKINSON-2030 Delphi Project. Brain Sciences, 2021, 11, 1027.	2.3	6
31	Falls Predict Acute Hospitalization in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, , 1-20.	2.8	5
32	Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinsonâ€™s Disease Patients: A 2-Year Follow-Up Study. Diagnostics, 2022, 12, 1147.	2.6	5
33	Mutational screening of the Mitochondrial transcription factors B1 and B2 (TFB1M and TFB2M) in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 468-470.	2.2	4
34	A series of cases with Huntington-like phenotype and intermediate repeats in HTT. Journal of the Neurological Sciences, 2021, 425, 117452.	0.6	3
35	Parkinsonâ€™s Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Parkinson's Disease, 2022, 12, 935-955.	2.8	3
36	Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinsonâ€™s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Diagnostics, 2021, 11, 2380.	2.6	2

#	Article	IF	Citations
37	Cancer in Parkinson's Disease: An Approximation to the Main Risk Factors. Neurodegenerative Diseases, 2021, 21, 36-41.	1.4	1